A randomized double-blind trial reported that sodium zirconium cyclosilicate helped chronic kidney disease patients with heart failure reach target doses of RAAS inhibitors while reducing hyperkalemia-related interruptions. The study concluded that more patients achieved full drug dosing when treated with the potassium binder. The findings are framed around a practical dosing barrier that can limit guideline-directed medical therapy in CKD, where potassium elevations force dose reductions or discontinuation. Clinicians and biotech teams are likely to view the result as execution-relevant evidence for adjunctive hyperkalemia management—particularly as RAAS inhibitor use becomes even more central across cardiometabolic indications.